Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Ascendis Pharma Ads (ASND)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,084,802
  • Shares Outstanding, K 42,033
  • Annual Sales, $ 1,730 K
  • Annual Income, $ -140,040 K
  • 36-Month Beta 0.86
  • Price/Sales 7,463.01
  • Price/Cash Flow N/A
  • Price/Book 8.72

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -1.18
  • Number of Estimates 5
  • High Estimate -1.02
  • Low Estimate -1.31
  • Prior Year -1.08
  • Growth Rate Est. (year over year) -9.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
54.67 +35.17%
on 12/24/18
75.83 -2.56%
on 01/16/19
+10.37 (+16.33%)
since 12/18/18
3-Month
53.21 +38.88%
on 11/14/18
75.83 -2.56%
on 01/16/19
+7.64 (+11.53%)
since 10/18/18
52-Week
48.00 +53.94%
on 02/06/18
76.99 -4.03%
on 08/29/18
+23.65 (+47.07%)
since 01/18/18

Most Recent Stories

More News
Ascendis Pharma A/S Announces Participation in 37th Annual J.P. Morgan Healthcare Conference

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs, today announced that the company will participate...

JPM : 104.59 (+1.62%)
ASND : 73.89 (+0.68%)
Ascendis Pharma A/S Announces Positive Preliminary Phase 1 Data for TransCon CNP

- TransCon CNP delivered continuous exposure of CNP at target levels for seven days with a single subcutaneous administration -

ASND : 73.89 (+0.68%)
Market Trends Toward New Normal in Ascendis Pharma A/S, Diodes, Laureate Education, Randgold Resources, Fastenal, and LTC Properties -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Ascendis Pharma A/S (NASDAQ:ASND),...

LAUR : 15.28 (+0.13%)
GOLD : 11.79 (-0.92%)
ASND : 73.89 (+0.68%)
DIOD : 31.80 (-0.44%)
LTC : 44.38 (-0.09%)
FAST : 59.35 (+3.51%)
Factors of Influence in 2018, Key Indicators and Opportunity within Ascendis Pharma A/S, Fluor, InterDigital, Ruth's Hospitality Group, Aramark, and ManTech International -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ascendis Pharma A/S (NASDAQ:ASND),...

RUTH : 23.61 (-0.04%)
ARMK : 31.89 (+1.43%)
ASND : 73.89 (+0.68%)
IDCC : 72.34 (-0.84%)
MANT : 55.79 (+0.70%)
FLR : 38.53 (+3.16%)
Ascendis Pharma A/S Announces Support for Children's Growth Awareness Week and Day 2018

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon(TM) technology to address significant unmet medical needs, today announced its support of "Children's...

ASND : 73.89 (+0.68%)
Ascendis Pharma A/S Announces First Quarter 2018 Financial Results and Business Update Conference Call on May 30

Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs, today announced that the company will hold a...

ASND : 73.89 (+0.68%)
Global Human Growth Hormones Deficiency Drugs Market, 2018-2023 Featuring Ascendis Pharma A/S, Novo Nordisk A/S, Versartis Inc., Opko Health Inc., Pfizer Inc.

The "Global Human Growth Hormones Deficiency (GHD) Drugs Market Assessment: Current Market, Pipeline Review, Clinical Trials, Market Potential - Forecast to 2023" report has been added to ResearchAndMarkets.com's...

ASND : 73.89 (+0.68%)
NVO : 48.05 (+0.84%)
OPK : 3.80 (+2.15%)
PFE : 42.53 (+0.14%)
Ascendis Pharma A/S Announces Dosing of First Subjects in Phase 1 Trial of TransCon CNP

- TransCon CNP is Company's Third Product Candidate in Clinic -

ASND : 73.89 (+0.68%)
Ascendis Pharma A/S Announces Poster Presentation on TransCon PTH Phase 1 Trial at the European Congress of Endocrinology

Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet medical needs, today announced an upcoming poster presentation...

ASND : 73.89 (+0.68%)
Ascendis Pharma A/S Announces Upcoming Investor Presentations

Ascendis Pharma A/S (Nasdaq:ASND), a clinical stage biopharmaceutical company that applies its innovative TransCon technology to address significant unmet medical needs, today announced that the company...

ASND : 73.89 (+0.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade ASND with:

Business Summary

Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology,...

See More

Key Turning Points

2nd Resistance Point 75.06
1st Resistance Point 74.48
Last Price 73.89
1st Support Level 73.16
2nd Support Level 72.42

See More

52-Week High 76.99
Last Price 73.89
Fibonacci 61.8% 65.92
Fibonacci 50% 62.49
Fibonacci 38.2% 59.07
52-Week Low 48.00

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar